Table 1 UCD PDX-derived cell line general characteristics
From: New generation breast cancer cell lines developed from patient-derived xenografts
Cell line | Origin | Patient age | Pathology of patient specimen | PDX ER/PR statusa | Cell line ER/PR statusa | Treatment |
|---|---|---|---|---|---|---|
UCD4 | Pleura | 68 | Invasive mammary carcinoma. Metastatic adenocarcinoma. Grade 2. Original pathologyb ER+PR+Her2− | ER+++PR+++ | ER+++PR+ | Tamoxifen, AI, fulvestrant, chemotherapy |
UCD12 | Primary tumor | 54 | IDC with mucinous features, grade 3, ER+(93%)PR+(15%)Her2− | ER++PR− | ER++PR− | None |
UCD65 | Lymph node | 47 | Metastatic carcinoma in LN. ER(97%)PR(5%)Her2− | ER+++PR++ | ER+++PR++ | Neoadjuvant chemotherapy |
UCD46 | Primary tumor | 41 | IDC multifocal. Grade 3. ER(0%)PR(20%)Her2− | ERlowPR− | ER−PR− | Neoadjuvant chemotherapy |
UCD115 | Primary tumor | 36 | IDC. ER−PR−Her2− | ERlowPR− | ER−PR− | Neoadjuvant chemotherapy |
UCD178 | Pleura | ND | ILC. Original pathologyb ER+PR+Her2− | ERlowPR− | ER−PR− | Tamoxifen, AI, palbociclib, chemotherapy |